Eli Lilly's (LLY) forward P/E is 25.4, which is well above those of the healthcare sector and the full S&amp;P 500 (which is at the bottom of the sector list on the second table). But this premium valuation may be well-justified by Lilly's growth projections.
Insulet (PODD) is also in the healthcare sector and its forward P/E is lower than that of Lilly, while its CAGR projections for revenue and EPS are higher than those for Lilly.
Click on the tickers for more about each company.
Read: Tomi Kilgore's detailed guide to the information available on the MarketWatch quote page
Don't miss: These 10 tech stocks have been models of consistency for a decade - none are chip stocks
-Philip van Doorn
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-20-26 1005ET

PODD

Eli Lilly (LLY) has a forward P/E of 25.4, higher than the healthcare sector and S&P 500 averages, justified by strong growth projections. Insulet (PODD) also in healthcare, has a lower forward P/E but higher CAGR projections for revenue and EPS compared to Lilly.

Dow Jones

Eli Lilly

Insulet

iShares US Pharma

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

SPDR S&P Health Equip

iShares Biotechnology ETF

Ark Genomic Revolution ETF

S&P 500

These 15 S&P 500 stocks could be contrarian -2-